Similar articles

• Saralasin in human hypertension: the early experience.

  Brunner HR, Laragh JH. Brunner HR, et al. Kidney Int Suppl. 1979 Mar;(9):S36-43. Kidney Int Suppl. 1979. PMID: 289862 No abstract available.
• The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.

  Brown JJ, Brown WC, Fraser R, Lever AF, Morton JJ, Robertson JI, Rosei EA, Trust PM. Brown JJ, et al. Aust N Z J Med. 1976 Aug;6(3 Suppl):48-52. doi: 10.1111/j.1445-5994.1976.tb03335.x. Aust N Z J Med. 1976. PMID: 1071403
• [Hemodynamics, renin and aldosterone following angiotensin II blockade and sodium chloride deficiency in hypertensive subjects].

  Beyer J, Liebau G, Steiner B, Schick K, Hayduk K. Beyer J, et al. Verh Dtsch Ges Kreislaufforsch. 1977;43:212-3. Verh Dtsch Ges Kreislaufforsch. 1977. PMID: 613577 German. No abstract available.
• Angiotensin as a renal, adrenal, and cardiovascular hormone: responses to saralasin in normal man and in essential and secondary hypertension.

  Hollenberg NK, Williams GH. Hollenberg NK, et al. Kidney Int Suppl. 1979 Mar;(9):S29-35. Kidney Int Suppl. 1979. PMID: 384070 Review. No abstract available.
• [The effect of an angiotensin antagonist on blood pressure, renin and aldosterone secretion and its pathogenetic importance].

  Beckerhoff R. Beckerhoff R. Schweiz Med Wochenschr Suppl. 1978;(7):1-24. Schweiz Med Wochenschr Suppl. 1978. PMID: 349683 Review. German. No abstract available.